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Introduction
The small conducting airways (defined in man as less than 2 mm in diameter) are now recognized as the major site of airflow limitation in chronic obstructive pulmonary disease (COPD) and are also involved in severe asthma (Hasegawa et al., 2006; Davidson and Bai, 2005) . Small airway function has been studied by classical organ bath pharmacology using parenchymal strips and to a lesser extent by myography.
However, in the case of the former technique, it is not possible to isolate responses of the airway smooth muscle from those of other contractile elements within the lung (e.g. vascular smooth muscle), whilst in the latter, the airway is isolated from interaction with parenchymal cells and is limited to airways down to a minimum of 100-200 microns in diameter. Videomicroscopy of perpendicularly sliced airways in precision-cut lung slices can be used to quantify changes in airway area in response to contractile and relaxant stimuli. The technique has the advantage that very small airways (down to approximately 50 µm diameter) can be studied. In addition, since the slices are viewed under a microscope, it is possible to study only the response of the small airways in the presence of parenchymal attachments without the contributions from vascular smooth muscle (Wohlsen et al., 2003) .
Agents that act as agonists of the β 2 adrenoceptor are effective in the management of COPD and asthma, primarily through their bronchodilatating properties. These drugs induce bronchodilatation by causing direct relaxation of airway smooth muscle through activation of adenylate cyclase, which in turn increases intracellular 3′,5′-cyclic adenosine monophosphate levels. Although, the pharmacological properties of β 2 adrenoceptors on isolated human bronchus have been reported several times in the past (Nials et al., 1993; Naline et al., 1994; Schmidt This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on October 4, 2007 as DOI: 10.1124 at ASPET Journals on November 5, 2017 jpet.aspetjournals.org Downloaded from JPET #129296 5 et al., 2000) , it is not known whether this class of compounds has the same properties on human small conducting airways.
Indacaterol (QAB149, Novartis) (Battram et al., 2006) , is a novel inhaled once-daily β 2 adrenoceptor agonist that completed Phase II clinical trials for the treatment of COPD and asthma and is currently in Phase III. The present study utilized human precision-cut lung slices to study the potency, efficacy, onset and duration of action of indacaterol and compared its properties with the marketed β 2 adrenoceptor agonists:
albuterol, that is used as rescue medication and has a duration of action of approximately 4-h and formoterol and salmeterol used a maintenance therapy, both having a duration of action of approximately 12-h . In addition, given the limited availability of human tissue, we have assessed whether the rat small airways could be used as a good surrogate for the pharmacological characterization of β 2 adrenoceptor agonists by comparing the responses to the compounds in human and rat precisioncut lung slices.
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Preparation of precision-cut lung slices from resected human lung
The experiments described in this report were approved by the local ethics committee (Royal Brompton & Harefield Ethics Committee). Macroscopically normal human lung (3-10 g) was obtained from subjects undergoing resection usually for carcinoma of the lung. The tissue was weighed and then washed 3 times with 3 volumes of icecold slicing buffer (Hanks balanced salt solution containing 100 units/ml penicillin and 0.1 mg/ml streptomycin). Tissue supplied prior to 2:00 pm on the day of resection was processed immediately as described below. Tissue received after 2:00 pm was kept overnight in ice-cold slicing buffer supplemented with 1 g/l of D-glucose and bubbled with O 2 /CO 2 (95 % / 5 %). There were no significant differences between the responses to spasmogen or β 2 adrenoceptor agonists of small airways prepared on the day of resection and those kept on ice overnight.
Immediately prior to preparation, the tissue was submerged in a reservoir containing ice-cold slicing buffer and 3 % (w/v) ultra low melting point agarose (Type IXA) injected into the tissue using a fine gauge needle (NR18; Microlance). incubator on a rotating platform (1 rpm). The following morning slices were again washed with 1 ml incubation buffer and returned to the incubator. Several sample airways were monitored using the image analysis equipment described below to ensure that a stable baseline area had been attained. In those experiments where these This article has not been copyedited and formatted. The final version may differ from this version. 
Preparation of precision-cut lung slices from rat lungs.
The studies reported here conform to the UK Animals (Scientific Procedures) Act 1986. Precision-cut lung slices were prepared from the lungs of male Brown Norway rats (250-350 g) essentially as described previously (Martin et al., 1996) except that the pulmonary circulation was not perfused prior to inflation and the concentration of 
Onset of action, potency and intrinsic efficacy determinations
The spasmogens used were serotonin and carbachol for rat and human small airways, respectively. In the series of experiments used to determine potency and intrinsic efficacy or onset times, serotonin (rat) concentrations were increased from 0.3 µM in 
Duration of action studies
These studies were only performed on precision-cut lung slices prepared from human The maximum contraction induced by carbachol at each time point after test compound or vehicle treatment was expressed as a percentage of the maximum contraction induced before the addition of test compound or vehicle. In order to strengthen the data for comparison of indacaterol and salmeterol, these two treatments were always tested on adjacent segments of the same airway.
Data analysis
Airway areas (in pixels 2 ) at baseline and after treatments were calculated using a computer algorithm written within the KS 300 environment. For potency, efficacy and onset times the bronchodilatation (in pixels 2 ) was expressed as a percentage of the total closure (in pixels 2 ). In the experiments to determine onset time, the time taken to reach 50 % of the maximum bronchodilatation was calculated using the following equation: Percent bronchodilatation at time t = [(pixels at time t -pixels at maximum closure) / (pixels uncontracted-pixels at maximum closure)] x 100 %. The maximum value for this was then set to 100 % and all other time points expressed as a percentage of this. These values are then plotted versus time and the value for 50 % of the maximum determined by interpolation.
Statistical analysis to determine the differences between onset times of the compounds was carried out using a Student's unpaired t-test
For the duration of action experiments, the maximum percentage contraction to carbachol at different times after incubation with β-adrenoceptor agonist was expressed as a percentage of the maximum contraction (to the same concentration of carbachol) prior to treatment. Two or three airways from each subject were used for vehicle control and for each β-adrenoceptor agonist; these were averaged to give a "subject mean". The data were then expressed as a mean of the different subjects. The differences between compounds were then analysed statistically using a Student's t- 
Results

Human small airways
In human small airways, all compounds reversed the carbachol-induced contraction in a concentration-dependent manner. Indacaterol and formoterol had the highest intrinsic efficacy (73 ± 27 % and 67 ± 11 %, respectively), followed by albuterol (48 ± 4 %) and salmeterol (35 ± 5 %). Formoterol and salmeterol had subnanomolar potency with IC 50 values of 0.3 ± 0.1 and 0.7 ± 0.2 nM, respectively. Indacaterol had an IC 50 value of 37 ± 8 nM and albuterol was of lower potency (125 ± 11 nM) (Fig.   1 ).
The onset of action for each of the compounds was derived using equiefficacious concentration inducing about 30 to 40 % relaxation -3 nM for formoterol and 30 nM for indacaterol, salmeterol and albuterol. The onset was fast for albuterol (1.6 ± 0.3 min), formoterol (2.0 ± 0.3 min) and indacaterol (3.0 ± 0.2 min) whereas it was significantly slower for salmeterol (6.6 ± 0.3 min, p < 0.05) (Fig. 2 ).
Albuterol had a short duration of action and no inhibition of the baseline response to carbachol was evident at the first time point studied, 1 h. Formoterol, was still active at 1 h but no significant inhibition of contraction was observed at subsequent time points, 2, 4 and 24 h. Indacaterol and salmeterol were active up to the 6 h time points and lost their activity by 24 h. The inhibition of carbachol induced bronchoconstriction by salmeterol and indacaterol was identical at the 1 and 2 h time points after incubation with these compounds. However, at both the 4 and 6 h time points, the inhibition by indacaterol was significantly greater than that by salmeterol.
The control response to carbachol remained constant over the time frame of the study, indicating the viability of the slices (Fig. 3) .
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Rat small airways
In rat small airways, all compounds concentration-dependently reversed the serotonininduced contraction. Formoterol was the most potent compound, with an IC 50 value of 0.6 ± 0.1 nM. Salmeterol (2.0 ± 0.2 nM) had similar potency to albuterol (2.5 ± 0.3 nM) and indacaterol was of lower potency (10.5 ± 2.3 nM). Formoterol had the highest intrinsic efficacy (62 ± 7 %) followed by indacaterol (53 ± 19 %), albuterol (42 ± 12 %) and salmeterol (36 ± 5 %) (Fig. 1) . The onset of action for each of the compounds were derived using equi-efficacious concentration inducing about 35 % relaxation -1 nM for formoterol and 30 nM for indacaterol, salmeterol and albuterol.
The onset of action was fast for formoterol (1.7 ± 0.3 min) and indacaterol (3.5 ± 0.8 min) whereas it was significantly slower for salmeterol (7.6 ± 0.6 min, p < 0.05) and albuterol (8.8 ± 1.0 min, P < 0.05) (Fig. 2) .
Discussion
In this report, we described for the first time the pharmacological profile of indacaterol, a new once-daily inhaled β 2 adrenoceptor agonist that completed Phase II clinical trials for the treatment of COPD and asthma and is currently in Phase III, in human and rat precision-cut lung slices and compare its properties with those of marketed drugs.
The human lung slice model used in the present study appears to be a useful model for the clinical situation. In this preparation, our results show that indacaterol had a fast onset of action similar that of albuterol and formoterol. This is in contrast to the slower onset observed with salmeterol. In the clinical situation, it is recognized that albuterol and formoterol have fast onsets of action, whereas salmeterol has a slower onset (Wegener et al., 1992; van Noord et al., 1996) and results from a number of recent clinical studies have shown that a statistically significant beneficial effect for indacaterol is observed within the first 5 min after inhalation (Beeh et al., 2007; Tarral et al., 2005) . Regarding the duration of action, although the drugs tested have a shorter duration of action in our model when compared to the clinical situation, the rank order obtained (indacaterol > salmeterol > albuterol) is in line with their clinical properties. As observed previously in other systems, when studied in vitro, formoterol behaves as a short-acting drug (Nials et al., 1993; Nials et al., 1994; Battram et al., 2006) . A number of theories have been put forward to explain this inconsistency but none of them are really satisfactory. In addition to being a good model for the clinical properties (onset and duration of action) of the inhaled β 2 adrenoceptor agonists, the human lung slice appears to be a good quality model that can be used to determine the pharmacological properties of these compounds. Indeed, both the potency and agreement with our previous results using Chinese hamster ovary cells stably transfected with human β 2 adrenoceptors (Battram et al., 2006) and isolated human bronchus (Naline et al., 2007) .
Given the limited availability of human tissue, one of the goals of this study was to assess whether tissue obtained from laboratory animals could be used as a surrogate for human lung tissue in studies to characterize the small airway relaxant effect of β 2 adrenoceptor agonists. In previous work, we have shown that the isolated guinea pig trachea was a good predictor for human isolated bronchus to determine the potency efficacy and onset of action for the compounds used in the present study (Battram et al., 2006) . Therefore we started this work by assessing the appropriateness of precision-cut lung slices from guinea pigs and found that it was difficult to obtain good quality slices from this species. This is probably due to post mortem bronchoconstriction, reported previously (Lai et al., 1984) . During the course of this work, it was demonstrated that this phenomenon could be overcome by the inclusion of a β 2 adrenoceptor agonist, isoproterenol, in the media used for preparation of guinea pig precision-cut lung slices (Ressmeyer et al., 2006) . However, since the goal of our study was to characterize the pharmacology of β 2 adrenoceptor agonists, the presence of isoproterenol in the preparation buffer could have introduced confusing factors such as desensitization or other interaction at the β 2 adrenoceptor. Therefore we utilized rat tissues in the current study.
Our results obtained with long acting β 2 adrenoceptor agonists (indacaterol, salmeterol and formoterol) on the rat lung slices, suggest that this species seems to be a useful model for human tissue for determination of their potency, efficacy and onset of action. Indeed, in both rat and human precision-cut lung slices all three compounds had similar potency. In addition, indacaterol and formoterol behave as compounds with a fast onset of action and a high intrinsic efficacy whereas salmeterol had a slow onset of action with a lower intrinsic efficacy when compared with indacaterol and formoterol. In contrast, although the intrinsic efficacy of albuterol was similar in rat and human precision-cut lung slices, this compound was about 25 times more potent in the rat when compared to human and had a fast onset in the human but a slow onset in the rat precision-cut lung slices. The reason for these discrepancies is not clear and deserves further studies.
Although it is well established that the relaxant effect of β 2 adrenoceptor agonists in the airways is mainly at the levels of the tracheal and bronchial smooth muscle, the precise site of action for this class of compounds in the lower airways is still a matter of debate. Autoradiographic studies have shown that in both human and rat lungs, β 2 adrenoceptors are present in the smooth muscle of large and small airways, the epithelium, the vascular smooth muscle and to a lesser extend in the alveolar wall (Carstairs et al., 1985; Mak et al., 1995) , suggesting that the site of action for the β 2 adrenoceptor agonists in the lower part of the respiratory tract could include the airway smooth muscle, the vascular smooth muscle or the structural cells within the airway wall. Studies trying to differentiate the site of action for the relaxant effect of β 2 adrenoceptor agonist have generated controversial results (Vettermann et al., 1989; Kaczka et al., 1999; Petak et al., 1999) . Although, we cannot conclude on the possible role of vascular smooth muscle and cells within the airway parenchyma, our data show that the small airway smooth muscle could contribute to the relaxant effect induced by the β 2 adrenoceptors in the lower respiratory tract.
In conclusion, our results show that the human lung slice seems to be a useful model to study the clinical and pharmacological properties of inhaled β 2 adrenoceptor agonists. Although, the pharmacological properties for the long acting β 2 This article has not been copyedited and formatted. The final version may differ from this version. 
